<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225612</url>
  </required_header>
  <id_info>
    <org_study_id>CLPR-011</org_study_id>
    <nct_id>NCT03225612</nct_id>
  </id_info>
  <brief_title>Safety and Performance of the Trialign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)</brief_title>
  <acronym>SCOUT-II</acronym>
  <official_title>Safety and Performance of the Trialign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) for Symptomatic Chronic Functional Tricuspid Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitralign, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genae</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regulatory and Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mitralign, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and performance of the Trialign System for
      the treatment of symptomatic chronic functional tricuspid regurgitation (FTR) in patients
      with a minimum of moderate tricuspid regurgitation.

      The procedure will be performed with the PTVAS device using a non-surgical percutaneous
      approach to tricuspid valve repair in patients who have FTR with a minimum of moderate
      tricuspid regurgitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single-arm, multi-center study, enrolling symptomatic patients with chronic
      functional tricuspid regurgitation. The study will include up to 60 subjects from up to 15
      sites in Europe and the United States. Follow-up evaluations will be conducted through 5
      years post implantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2017</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all-cause mortality at 30 days.</measure>
    <time_frame>30-days</time_frame>
    <description>Incidence of all-cause mortality at 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>30 Days</time_frame>
    <description>Technical success, defined as freedom from death at 30 days with:
successful access, delivery and retrieval of the device delivery system;
deployment and correct positioning of the intended device(s) which is maintained and;
no need for additional unplanned or emergency surgery or re-intervention related to the device or access procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic variable: tenting height (maximum, any view)</measure>
    <time_frame>Change from Baseline at 30 days</time_frame>
    <description>Echocardiographic variables assessed by the Echocardiographic Core Lab at baseline and 30-days reflecting the severity of tricuspid pathology and the response to the Trialign device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic variable: tenting area (maximum, any view)</measure>
    <time_frame>Change from Baseline at 30 days</time_frame>
    <description>Echocardiographic variable assessed by the Echocardiographic Core Lab at baseline and 30-days reflecting the severity of tricuspid pathology and the response to the Trialign device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic variable: Quantification of tricuspid valve and annular area (maximum, any view)</measure>
    <time_frame>Change from Baseline at 30 days</time_frame>
    <description>Echocardiographic variable assessed by the Echocardiographic Core Lab at baseline and 30-days reflecting the severity of tricuspid pathology and the response to the Trialign device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tricuspid regurgitation as determined by echocardiographic methods</measure>
    <time_frame>Change from Baseline at 30 days</time_frame>
    <description>As measured by the PISA method and the Quantitative Flow method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent tricuspid regurgitation from baseline to 30-days</measure>
    <time_frame>Change from Baseline at 30 days</time_frame>
    <description>Percent tricuspid regurgitation from baseline to 30-days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 60 months post procedure</time_frame>
    <description>Rate of adverse events, including serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) classification</measure>
    <time_frame>Change from Baseline at discharge and then 1, 3, 6, 12, 24, 36, 48 and 60 months post procedure</time_frame>
    <description>Change in New York Heart Association (NYHA) classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-Minute Walk Test (6MWT)</measure>
    <time_frame>Change from Baseline at discharge and then 1, 3, 6, 12, 24, 36, 48 and 60 months post procedure</time_frame>
    <description>Change in the Six-Minute Walk Test (6MWT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living with Heart Failure Questionnaire (MLWHF)</measure>
    <time_frame>Change from Baseline at discharge and then 1, 3, 6, 12, 24, 36, 48 and 60 months post procedure</time_frame>
    <description>Score on the Minnesota Living with Heart Failure Questionnaire (MLWHF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol Five Dimensions Questionnaire (EQ-5D)</measure>
    <time_frame>Change from Baseline at discharge and then 1, 3, 6, 12, 24, 36, 48 and 60 months post procedure</time_frame>
    <description>Score on the EuroQol Five Dimensions Questionnaire (EQ-5D)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Symptomatic Functional Tricuspid Regurgitation</condition>
  <condition>Tricuspid Valve Insufficiency</condition>
  <condition>Heart Valve Disease</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-randomized, open label clinical study that intends to treat up to 60 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)</intervention_name>
    <description>Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) is delivered by a percutaneous transcatheter procedure. The Trialign PTVAS procedure utilizes catheters and wires to deliver up to two sets of pledgeted sutures across the tricuspid annulus near the septal/posterior and the posterior/anterior commissures. Each set of implants is pulled together to plicate the posterior tricuspid annulus.</description>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic functional tricuspid regurgitation (FTR) with a minimum of moderate tricuspid
             regurgitation;

          -  ≥18 and ≤85 years old;

          -  NYHA II, III, or ambulatory IV;

          -  Symptomatic despite Guideline Directed medical Therapy (GDMT), at minimum, patient on
             diuretic use;

          -  patient is at high risk for open heart valve surgery

          -  LVEF ≥35%

          -  Tricuspid valve annular diameter ≤55 mm (or 29 mm/m^2)

        Exclusion Criteria:

          -  Pregnant or lactating female;

          -  Severe uncontrolled hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg);

          -  Previous tricuspid valve repair or replacement;

          -  Severe coronary artery disease;

          -  MI or known unstable angina within the 30-days prior to the index procedure;

          -  Any PCI within 30 days prior to the index procedure or planned 3 months post the index
             procedure;

          -  Chronic oral steroid use (≥6 months);

          -  Life expectancy of less than 12-months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. med Joachim Schofer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Keating</last_name>
    <phone>978-863-2445</phone>
    <email>pkeating@mitralign.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gisella Blanchette</last_name>
    <phone>978.863.2435</phone>
    <email>gblanchette@mitralign.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Schuppe</last_name>
      <phone>+49 030 130 22 5101</phone>
      <email>maria.schuppe@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Hueseyin Ince, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Kische, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Brandenburg in Bernau</name>
      <address>
        <city>Bernau bei Berlin</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Bettin</last_name>
      <phone>+49 33 3869 4604</phone>
      <email>d.bettin@immanuel.de</email>
    </contact>
    <investigator>
      <last_name>Christian Butter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Neuss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CardioVascular Center Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine de Bruijn</last_name>
      <phone>+49 69 9794 7653</phone>
      <email>s.debruijn@cvcfrankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Horst Sievert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Reinartz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie Bohme</last_name>
      <phone>+49 40 889006 830</phone>
      <email>Boehme@herz-hh.de</email>
    </contact>
    <investigator>
      <last_name>Joachim Schofer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Tiburtius, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig - Universitätsklinik</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Kathrin Funkat</last_name>
      <phone>+49 341 865 1587</phone>
      <email>Anne-kathrin.funkat@leipzig-heart.de</email>
    </contact>
    <investigator>
      <last_name>Philipp Lurz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joerg Seeburger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Heart Center Munich</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annemarie Stroh, PhD</last_name>
      <phone>+49 (0) 89 1218-2965</phone>
      <email>stroh@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Sabine Bleiziffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Getrud Goppel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vega Rusconi</last_name>
      <phone>+39 022 643 7362</phone>
      <email>Rusconi.vega@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Azeem Latib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eustachio Agricola, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Primerano</last_name>
      <phone>+39 050099 5326</phone>
      <email>chiaraprim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sonia Petronio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Spontoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manola Smits</last_name>
      <phone>+31765955100</phone>
      <email>MSmits1@amphia.nl</email>
    </contact>
    <investigator>
      <last_name>Peter den Heijer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>BJL van den Branden, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greetje de Jong</last_name>
      <phone>+31 50 361 3348</phone>
      <email>g.h.de.jong@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>AFM van den Heuvel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>P van der Harst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C. Hospitalar Vila Nova de Gaia/Espinho, E.P.E.</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia M Dias</last_name>
      <phone>+351 934361674</phone>
      <email>sdias@CHVNG.MIN-SAUDE.PT</email>
    </contact>
    <investigator>
      <last_name>Vasco Da Gama, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Braga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

